Rapamycin has relatively recently been identified as an mTOR inhibitor that may be used to treat Kras Pten endocrine ductal adenocarcinoma, resulting in inhibition of proliferation and tumor size shrinkage [195]. The gene discussed is MTOR; the disease is neoplasm.